Maxigen Biotech (Taiwan) Today

1783 Stock  TWD 45.70  0.10  0.22%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 9

 
100  
 
Zero
Low
Maxigen Biotech is selling for under 45.70 as of the 29th of March 2024; that is -0.22 percent decrease since the beginning of the trading day. The stock's lowest day price was 45.7. Maxigen Biotech has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Maxigen Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and cosmeceutical skincare products in Taiwan and internationally. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan, Taiwan. MAXIGEN BIOTECH is traded on Taiwan Stock Exchange in Taiwan.. The company has 84.7 M outstanding shares. More on Maxigen Biotech

Moving against Maxigen Stock

  0.572887E Taishin Financial HoldingPairCorr
  0.452330 Taiwan SemiconductorPairCorr
  0.420057 Fubon MSCI TaiwanPairCorr
  0.410050 YuantaP-shares Taiwan TopPairCorr
  0.410053 YuantaP-shares TaiwanPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Maxigen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Maxigen Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Maxigen Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chairman of the BoardLide Xu
Thematic IdeaIT (View all Themes)
Business ConcentrationIT, Drug Manufacturers - Major, Healthcare, Computing (View all Sectors)
Maxigen Biotech (1783) is traded on Taiwan Stock Exchange in Taiwan and employs 20 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Maxigen Biotech's market, we take the total number of its shares issued and multiply it by Maxigen Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Maxigen Biotech operates under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 84.7 M outstanding shares. Maxigen Biotech has accumulated about 390.34 M in cash with 117.59 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.62.
Check Maxigen Biotech Probability Of Bankruptcy
Ownership Allocation
Maxigen Biotech holds a total of 84.7 Million outstanding shares. Maxigen Biotech holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Maxigen Ownership Details

Maxigen Stock Price Odds Analysis

Depending on a normal probability distribution, the odds of Maxigen Biotech jumping above the current price in 90 days from now is about 71.5%. The Maxigen Biotech probability density function shows the probability of Maxigen Biotech stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Maxigen Biotech has a beta of -0.2702. This suggests as returns on benchmark increase, returns on holding Maxigen Biotech are expected to decrease at a much lower rate. During the bear market, however, Maxigen Biotech is likely to outperform the market. Additionally, maxigen Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 45.7HorizonTargetOdds Above 45.7
28.17%90 days
 45.70 
71.50%
Based on a normal probability distribution, the odds of Maxigen Biotech to move above the current price in 90 days from now is about 71.5 (This Maxigen Biotech probability density function shows the probability of Maxigen Stock to fall within a particular range of prices over 90 days) .

Maxigen Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Maxigen Biotech market risk premium is the additional return an investor will receive from holding Maxigen Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Maxigen Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Maxigen Biotech's alpha and beta are two of the key measurements used to evaluate Maxigen Biotech's performance over the market, the standard measures of volatility play an important role as well.

Maxigen Stock Against Markets

Picking the right benchmark for Maxigen Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Maxigen Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Maxigen Biotech is critical whether you are bullish or bearish towards Maxigen Biotech at a given time. Please also check how Maxigen Biotech's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Maxigen Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Maxigen Biotech Corporate Directors

Maxigen Biotech corporate directors refer to members of a Maxigen Biotech board of directors. The board of directors generally takes responsibility for the Maxigen Biotech's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Maxigen Biotech's board members must vote for the resolution. The Maxigen Biotech board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Maxigen Stock?

Before investing in Maxigen Biotech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Maxigen Biotech. To buy Maxigen Biotech stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Maxigen Biotech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Maxigen Biotech stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Maxigen Biotech stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Maxigen Biotech stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Maxigen Biotech, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.

Already Invested in Maxigen Biotech?

The danger of trading Maxigen Biotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Maxigen Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Maxigen Biotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Maxigen Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Maxigen Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Maxigen Stock analysis

When running Maxigen Biotech's price analysis, check to measure Maxigen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maxigen Biotech is operating at the current time. Most of Maxigen Biotech's value examination focuses on studying past and present price action to predict the probability of Maxigen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maxigen Biotech's price. Additionally, you may evaluate how the addition of Maxigen Biotech to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Please note, there is a significant difference between Maxigen Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Maxigen Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maxigen Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.